ClinicalTrials.gg
Not yet recruitingNCT07745686VALSEUpdated Aug 4, 2026

VALSE: Integration of Neuromodulation and Exoskeleton Systems for Mobility in Individuals With Chronic Spinal Cord Injury

An interventional study of TWIICE Rise 1.0 robotic exoskeleton combined with epidural electrical stimulation (EES) in Spinal Cord Injury, sponsored by Ecole Polytechnique Fédérale de Lausanne. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Ecole Polytechnique Fédérale de Lausanne · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Spinal Cord Injuries with a site in Switzerland — 25 open to participants now, 31 under way, none of them phase 3. Spinal Cord Injuries · Switzerland.

Planned enrollment
52nd of 72
12 · median 21
Started
2026
with 7 others
No phase
59 of 111
18 open now
Primary completion
2028-05
later than 18 of 30 live
Registered
108th of 111
by date
Lead sponsor
8 of 111
Ecole Polytechnique Fédérale de Lausanne

Among the 111 studies in Spinal Cord Injuries with a site in Switzerland, this one is the 52nd largest by planned enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2026, is one of 59 with no phase, reaches primary completion later than 18 of the 30 other live ones, and was the 108th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

25 of the 111 studies in Spinal Cord Injuries with a site in Switzerland are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Spinal Cord Injuries with a site in Switzerland, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the preliminary safety and feasibility of using the VALSE system, which combines spinal cord stimulation with the TWIICE robotic exoskeleton, to support motor recovery and reduce reliance on laboratory-based equipment during rehabilitation in participants with traumatic spinal cord injury. The TWIICE exoskeleton is integrated through the NR system, a platform developed by EPFL. The goal is to assess the clinical safety and practical application of this combined neuroprosthetic approach in a small number of participants, in order to guide future refinements of the device and protocol, support the development of scalable interventions integrating spinal stimulation with robotic assistance, and inform strategies for delivering rehabilitation in more accessible, real-world environments.

Read the detailed description

Spinal cord injury (SCI) disrupts communication between the brain and spinal cord below the lesion, often resulting in severe and permanent motor impairments. Despite advances in rehabilitation, recovery of walking remains limited and restoring mobility is consistently identified as a top priority by individuals living with SCI.

Epidural electrical stimulation (EES) of the spinal cord has emerged as a promising approach to restore movement after paralysis. By activating spinal motor circuits below the lesion, EES can enable standing, stepping, and walking in individuals with chronic SCI. ONWARD Medical has developed the ARC-IM spinal stimulation platform, which is currently being evaluated in several clinical studies, including BoxSwitch (NCT05942339), Think2Go (NCT06243952), and STIMO-BSI (NCT04632290).

In the BoxSwitch trial, optimized spatiotemporal EES protocols enabled participants with chronic SCI to perform standing, stepping, and walking movements. Building on these findings, the Think2Go and STIMO-BSI studies integrated the WIMAGINE implantable electrocorticography (ECoG) system developed by Clinatec (CEA, Grenoble, France) with spinal stimulation, creating a brain-spine interface capable of decoding motor intentions and translating them into spinal stimulation. These studies demonstrated that implantable brain-spine interfaces can restore voluntary control of lower-limb movements and support functional walking after severe paralysis.

Although these technologies have shown encouraging results, their use remains largely restricted to specialized rehabilitation settings. In parallel, robotic exoskeletons have been developed to support overground walking in individuals with SCI. The TWIICE exoskeleton is a lightweight and modular system specifically designed for use beyond rehabilitation centers and may complement spinal stimulation by providing functional support during walking.

In this study, the investigators will evaluate the preliminary safety and feasibility of the VALSE system, which combines the ARC-IM spinal cord stimulation platform with the TWIICE robotic exoskeleton in individuals with chronic traumatic SCI. Participants will be recruited from ongoing clinical studies at Lausanne University Hospital (CHUV), including BoxSwitch (NCT05942339), Think2Go (NCT06243952), and STIMO-BSI (NCT04632290), after completion of the relevant study phases.

As an early feasibility investigation, the study aims to generate preliminary safety and usability data on the combined use of spinal neuromodulation and robotic assistance during mobility tasks. The results will support the development of future neuroprosthetic solutions designed to improve walking ability, independence, and quality of life for people living with SCI.

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • exoskeleton
  • Spinal cord stimulation
  • Brain spine interface
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently enrolled participants who have completed the relevant phase of their parent study at CHUV: BoxSwitch (NCT05942339, after the optimisation phase), Think2Go (NCT06243952, after the rehabilitation phase, or STIMO-BSI (NCT04632290, after the calibration and training phase of the optional extension with system upgrade),
  • Must have a functional neuromodulation system,
  • Must be at least 18 years old,
  • Must be suffering from non-progressive traumatic spinal cord injury, sustained at least 12 months before signing the consent form,
  • Must weigh less than 100 kg,
  • Must have a standing height between 160 and 190 cm,
  • Must be able to grasp and lift bilateral crutches in a seated position,
  • Must have stable medical, physical and psychological condition as considered by the investigator,
  • Must be able to understand and interact with the study team in French or English,
  • Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments,
  • Must provide as documented by signature prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Must not be diagnosed with severe osteoporosis/penia:

Dual Energy X-ray Absorptiometry (DEXA) results indicating a t-score below -3.5 at either the femoral neck or the total proximal femur.

Dual Energy X-ray Absorptiometry (DEXA) results indicating a bone mineral density (BMD) \< 0.60 gm/cm2 at any knee region (distal femur, proximal tibia)

  • Must not have deep vein thrombosis in lower extremities within the past 6 months.
  • Must not have experienced lower extremity fractures within the last two years.
  • Must not have current pressure ulcer of the arms, trunk, pelvic area, or lower extremities
  • Must not present with a flexion contracture >15° at the hip or knee
  • Must not have severe concurrent medical conditions that contraindicate moderate to intense exercise (e.g., uncontrolled hypertension, coronary artery disease, congestive heart failure).
  • Must not have heterotopic ossification that impairs joint mobility
  • Must not be implanted with a life-supporting medical device (devices implanted in the parent study are not considered life-supporting),
  • Must not be pregnant,
  • Must not be the investigator himself, his/her family members, employees, or other dependent persons.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    All participant

    All participants receive the same intervention. Each participant will complete 3 predefined study periods within 1 year of enrolment. Each study period lasts 3 weeks, and study periods are separated by a minimum interval of 1 month.

    Combination Product: TWIICE Rise 1.0 robotic exoskeleton combined with epidural electrical stimulation (EES)

Interventions

  • Combination productTWIICE Rise 1.0 robotic exoskeleton combined with epidural electrical stimulation (EES)

    Participants will use the VALSE system, which combines the TWIICE Rise 1.0 robotic exoskeleton with epidural electrical stimulation (EES) delivered through previously implanted neuromodulation systems. The system is intended to support upright mobility and overground walking in individuals with chronic spinal cord injury (SCI) who are currently enrolled in, or have completed key phases of, neuromodulation clinical trials at CHUV, including Think2Go (NCT06243952), STIMO-BSI (NCT04632290), and BoxSwitch (NCT05942339). The TWIICE exoskeleton provides robotic gait assistance, while EES facilitates activation of spinal motor circuits below the level of injury. Exoskeleton movements are initiated and controlled through participant-generated inputs, including finger-click commands and, where applicable, brain-derived control signals from previously implanted brain-spine interface systems. The VALSE system is used in supervised clinical and controlled real-world.

06

What researchers measure

Primary outcomes

  1. Preliminary safety

    Occurrence of Serious Adverse Events (SAE) and Adverse Events (AE) that are deemed related or possibly related to the procedure or to the TWIICE exoskeleton in combination with the neuromodulation therapies (VALSE system)

    Time frame: From enrollment until the end of study timepoint, up to 1 year after enrollment.

Secondary outcomes

  1. Assessment of the experimental session conditions

    Location and type of ground walked on.

    Time frame: At each in-clinic training session during the three study periods, up to 1 year after enrollment.

  2. Number of steps

    Total number of steps recorded by the exoskeleton during each experimental (EX) session.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  3. Step frequency

    Average step frequency (cadence) recorded by the exoskeleton during each experimental (EX) session.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  4. Mid-stride pauses

    Number of mid-stride pauses recorded by the exoskeleton during each experimental (EX) session.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  5. Distance walked

    Total distance walked recorded by the exoskeleton during each experimental (EX) session.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  6. Walking time

    Total walking time recorded by the exoskeleton during each experimental (EX) session.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  7. Standing time

    Total standing time recorded by the exoskeleton during each experimental (EX) session.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  8. Kinematic gait parameters

    Kinematic gait parameters recorded during overground walking and functional locomotor tasks (change of walking speed, stepping over and turn around obstacles, climb stairs, walk with cognitive load (e.g., counting backward by threes)) using the VALSE system.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  9. Electromyographic (EMG) activity

    Muscle activation patterns recorded by surface electromyography during overground walking and functional locomotor tasks while using the VALSE system.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  10. Brain-computer interface (BCI) performance

    Brain-computer interface performance metrics recorded during overground walking and functional locomotor tasks while using the VALSE system.

    Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.

  11. Donning and Doffing Time

    Assessment of the time it takes to put on and take off the system. Donning time is recorded from the start of preparation until the participant is fully ready for ambulation. Doffing time is recorded from the start of removal until the participant is fully disengaged from the system.

    Time frame: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.

  12. Level of Assistance (LOA)

    Assessment to evaluates the amount of physical support required by the participant during walking and mobility activities with the device.

    Time frame: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.

  13. System Usability Scale (SUS)

    A validated 10-item questionnaire measuring usability across multiple domains. Scores range from 0-100, with higher values indicating greater usability. Will be filled in by participants and physiotherapists.

    Time frame: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.

  14. ASA Task Load Index (NASA-TLX)

    A 6-dimension tool assessing perceived workload (mental demand, physical demand, temporal demand, performance, effort, frustration). Will be filled in by participants and physiotherapists.

    Time frame: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.

07

Study locations

1 site
08

References and documents

Publications

  • Gorgey AS, Gill S, Holman ME, Davis JC, Atri R, Bai O, Goetz L, Lester DL, Trainer R, Lavis TD. The feasibility of using exoskeletal-assisted walking with epidural stimulation: a case report study. Ann Clin Transl Neurol. 2020 Feb;7(2):259-265. doi: 10.1002/acn3.50983. Epub 2020 Feb 5. PubMed 32023011 ↗
  • Hong E, Gorman PH, Forrest GF, Asselin PK, Knezevic S, Scott W, Wojciehowski SB, Kornfeld S, Spungen AM. Mobility Skills With Exoskeletal-Assisted Walking in Persons With SCI: Results From a Three Center Randomized Clinical Trial. Front Robot AI. 2020 Aug 4;7:93. doi: 10.3389/frobt.2020.00093. eCollection 2020. PubMed 33501260 ↗
  • Vouga T, Fasola J, Baud R, Manzoori AR, Pache J, Bouri M. TWIICE One powered exoskeleton: effect of design improvements on usability in daily life as measured by the performance in the CYBATHLON race. J Neuroeng Rehabil. 2022 Jun 27;19(1):63. doi: 10.1186/s12984-022-01028-0. PubMed 35761399 ↗
  • Zhang T, Jia Y, Wang N, Chai X, He Q, Cao T, Mu Q, Lan Q, Zhao J, Yang Y. Recent advances in potential mechanisms of epidural spinal cord stimulation for movement disorders. Exp Neurol. 2025 Oct;392:115330. doi: 10.1016/j.expneurol.2025.115330. Epub 2025 Jun 4. PubMed 40480308 ↗
  • Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, Cassara A, Becce F, Lloyd B, Newton T, Ravier J, Kinany N, D'Ercole M, Paley A, Hankov N, Varescon C, McCracken L, Vat M, Caban M, Watrin A, Jacquet C, Bole-Feysot L, Harte C, Lorach H, Galvez A, Tschopp M, Herrmann N, Wacker M, Geernaert L, Fodor I, Radevich V, Van Den Keybus K, Eberle G, Pralong E, Roulet M, Ledoux JB, Fornari E, Mandija S, Mattera L, Martuzzi R, Nazarian B, Benkler S, Callegari S, Greiner N, Fuhrer B, Froeling M, Buse N, Denison T, Buschman R, Wende C, Ganty D, Bakker J, Delattre V, Lambert H, Minassian K, van den Berg CAT, Kavounoudias A, Micera S, Van De Ville D, Barraud Q, Kurt E, Kuster N, Neufeld E, Capogrosso M, Asboth L, Wagner FB, Bloch J, Courtine G. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022 Feb;28(2):260-271. doi: 10.1038/s41591-021-01663-5. Epub 2022 Feb 7. PubMed 35132264 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2028, 20 months later.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 20 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Aug 4, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
May 2028
CompletionEst.
Sep 2028
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07745686
Lead sponsor
Ecole Polytechnique Fédérale de Lausanne
Responsible party
Jocelyne Bloch (Prof., Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Aug 4, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
May 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Aug 4, 2026

Study contacts

Jocelyne Bloch, Prof.
Contact
jocelyne.bloch@chuv.ch
+41 79 556 29 51
Henri Lorach, PhD
Contact
henri.lorach@epfl.ch
+41 77 495 50 48
Jocelyne Bloch, Prof.
principal investigator · Centre Hospitalier Universitaire Vaudois (CHUV)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion